Product Code: GDHC311CFR
In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.'s Zontivity (vorapaxar), AstraZeneca's Brilinta (ticagrelor), and Bayer and Janssen's (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.
Total 5EU sales for the PAD therapeutics market in 2014 was approximately $198.8m. By 2024, sales of drugs that are used to relieve the symptoms of PAD will decline quite dramatically. This group of medicines will only contribute approximately 5% to total 5EU PAD sales by the end of the forecast period.
Scope
- Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU PAD market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for PAD.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in 5EU.
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
2. Introduction
- 2.1. Catalyst
- 2.2. Related Reports
- 2.3. Upcoming Related Reports
3. Disease Overview
- 3.1. Etiology and Pathophysiology
- 3.1.1. Etiology
- 3.1.2. Pathophysiology
- 3.2. Classification and Staging Systems
- 3.3. Symptoms and Clinical Presentation
- 3.4. Prognosis
- 3.5. Quality of Life
4. Disease Management
- 4.1. Diagnosis and Treatment Overview
- 4.1.1. Diagnosis
- 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
- 4.2. Five Major European Markets
5. Competitive Assessment
- 5.1. Overview
- 5.2. Lifestyle Modifications
- 5.2.1. Exercise
- 5.2.2. Smoking cessation
- 5.3. Risk Factor Modification Drugs
- 5.3.1. Lipid-Lowering Medical Therapies
- 5.3.2. Antihypertensive Medical Therapies
- 5.3.3. Antithrombotic Medical Therapies
- 5.3.4. Glucose-Lowering Medical Therapies
- 5.3.5. Thrombolytic Therapies
- 5.4. Medical Therapies Treating the Symptoms of PAD - Major Brands
- 5.4.1. Pletal / Pletaal (cilostazol)
- 5.4.2. Praxilene (naftidrofuryl oxalate)
- 5.4.3. Trental (pentoxifylline)
- 5.4.4. Prostaglandin and Prostanoid Medical Therapies
- 5.4.5. Other Pharmacological Therapies
- 5.5. Non-Pharmacological Therapies
6. Unmet Need and Opportunity Analysis
- 6.1. Overview
- 6.2. Enhanced Patient and Physician Education and Awareness of PAD, Facilitating Augmented Diagnosis and Treatment Rates
- 6.2.1. Unmet Need
- 6.2.2. Gap Analysis
- 6.2.3. Opportunity
- 6.3. A Greater Number of Trials Exclusively Involving PAD Patients Will Yield Improved Guidelines for the Management of PAD
- 6.3.1. Unmet Need
- 6.3.2. Gap Analysis
- 6.3.3. Opportunity
- 6.4. Superior Pharmacological Agents that Treat the Symptoms of Intermittent Claudication and Critical Limb Ischemia, but also Obviate Cardiovascular Events
- 6.4.1. Unmet Need
- 6.4.2. Gap Analysis
- 6.4.3. Opportunity
- 6.5. Unravelling the Convoluted Nature Behind the Etiology and Pathophysiology of Atherosclerosis, Which Will Potentially Lead to Treatments that Prevent or Reverse Plaque Formation
- 6.5.1. Unmet Need
- 6.5.2. Gap Analysis
- 6.5.3. Opportunity
7. Pipeline Assessment
- 7.1. Overview
- 7.2. Promising Drugs in Late-Stage Clinical Development
- 7.2.1. Xarelto (rivaroxaban)
- 7.2.2. Brilinta (ticagrelor)
- 7.3. Promising Drugs in Early-Stage Clinical Development
- 7.3.1. Therapeutic Angiogenesis
8. Market Outlook
- 8.1. Five Major European Markets
- 8.1.1. Forecast
- 8.1.2. Key Events
- 8.1.3. Drivers and Barriers
9. Appendix
- 9.1. Bibliography
- 9.2. Abbreviations
- 9.3. Methodology
- 9.4. Forecasting Methodology
- 9.4.1. Diagnosed PAD Patients
- 9.4.2. Percent Drug-Treated Patients
- 9.4.3. Drugs Included in Each Therapeutic Class
- 9.4.4. Launch and Patent Expiry Dates
- 9.4.5. General Pricing Assumptions
- 9.4.6. Individual Drug Assumptions
- 9.4.7. Generic Erosion
- 9.4.8. Pricing of Pipeline Agents
- 9.5. Physicians and Specialists Included in this Study
- 9.6. About the Authors
- 9.6.1. Analyst
- 9.6.2. Therapy Area Director
- 9.6.3. Epidemiologist
- 9.6.4. Global Head of Healthcare
- 9.6.5. Global Director of Therapy Analysis and Epidemiology
- 9.7. About GlobalData
- 9.8. Disclaimer
List of Tables
- Table 1: The Various Causes of PAD
- Table 2: The Rutherford-Baker System and the Fontaine Classification for PAD
- Table 3: The Various Etiologies of ALI
- Table 4: The Symptoms of PAD
- Table 5: Population Characteristics of Individuals who Require Regular Screening for PAD
- Table 6: Treatment Guidelines for PAD
- Table 7: 8MM, Most Prescribed Drugs for PAD by Class, 2015
- Table 8: Country Profile - 5EU
- Table 9: Leading Drugs for PAD Treatment, 2015
- Table 10: 8MM, Most Frequently Prescribed Lipid-lowering Medical Therapies
- Table 11: Most Frequently Used Beta Blockers
- Table 12: Product Profile - Beta Blockers
- Table 13: Most Frequently Used ACE Inhibitors
- Table 14: Product Profile - ACE Inhibitors
- Table 15: Most Frequently Used ARBs
- Table 16: Product Profile - ARBs
- Table 17: Product Profile - Plavix (clopidogrel)
- Table 18: Product Profile - Zontivity (vorapaxar)
- Table 19: Efficacy and Bleeding Endpoints at Three Years in the TRA 2P-TIMI 50 Study
- Table 20: Product Profile - Metformin
- Table 21: Product Profile - Pletal (cilostazol)
- Table 22: Safety Profile - Pletal (cilostazol)
- Table 23: SWOT Analysis of Pletal, 2015
- Table 24: Global Sales Forecast ($m) for Cilostazol, 2014-2024
- Table 25: Product Profile - Praxilene (naftidrofuryl)
- Table 26: Safety Profile - Praxilene (naftidrofuryl)
- Table 27: SWOT Analysis of Praxilene, 2015
- Table 28: Global Sales Forecast ($) for Naftidrofuryl, 2014-2024
- Table 29: Product Profile - Trental (pentoxifylline)
- Table 30: Most Frequently Recorded Side Effects for Pentoxifylline and Cilostazol.
- Table 31: The Incidence (%) of Side Effects with Trental
- Table 32: SWOT Analysis of Trental, 2015
- Table 33: Global Sales Forecast ($m) for Pentoxifylline, 2014-2024
- Table 34: Indications for Revascularization in PAD
- Table 35: Major Unmet Needs and Opportunities in PAD
- Table 36: Promising Drugs in Late-stage Clinical Development in the PAD Pipeline, 2015
- Table 37: Comparison of Therapeutic Classes in Development for PAD, 2015
- Table 38: Product Profile - Xarelto (rivaroxaban)
- Table 39: SWOT Analysis of Xarelto, 2015
- Table 40: 8MM, Sales Forecast ($m) for Xarelto, 2014-2024
- Table 41: Product Profile - Brilinta (ticagrelor)
- Table 42: Brilinta's Efficacy and Safety Endpoints as Three-Year Kaplan-Meier Estimates in the PEGASUS-TIMI 54 Study
- Table 43: SWOT Analysis of Brilinta, 2015
- Table 44: 8MM, Sales Forecast ($) for Brilinta, 2014-2024
- Table 45: Sales Forecast ($m) for PAD in the 5EU, 2014-2024
- Table 46: Key Events Impacting Sales for PAD in the 5EU, 2014-2024
- Table 47: 5EU PAD Market - Drivers and Barriers, 2014-2024
- Table 48: Abbreviations
- Table 49: Key Launch Dates
- Table 50: Key Patent Expiries
- Table 51: High-Prescribing Physicians Non-KOLs Surveyed, By Country
List of Figures
- Figure 1: Clinical Manifestations of PAD
- Figure 2: Progression of PAD, Atherosclerotic Plaque Rupture and Thrombosis.
- Figure 3: The Most Common Tests Used to Diagnose PAD in 5EU Patients, 2014
- Figure 4: Breakdown of 5EU PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014
- Figure 5: The Various Marketed and Pipeline Antithrombotic Medical Therapies for PAD
- Figure 6: The Treatment Algorithm for IC Patients
- Figure 7: The Treatment Algorithm for CLI Patients
- Figure 8: The Treatment Algorithm for ALI Patients
- Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in PAD, 2014-2024
- Figure 10: Sales for PAD in the 5EU by Drug Class, 2014 and 2024
